However, as highlighted earlier, the majority of high‐grade aggressive gliomas do not exhibit such defects in IDH genes and associated metabolism but, as discussed below, disruption to HR and associated DDR pathways may represent a credible mechanism to produce a similar phenotype in these tumours. The gene discussed is IDH2; the disease is central nervous system cancer.